Lantern Pharma Secures FDA Orphan Drug Tag For Pancreatic Cancer Candidate

The FDA has granted Orphan Drug Designation to Lantern Pharma Inc's LTRN LP-184 for pancreatic cancer.
LP-184 is a small molecule drug candidate and next-generation alkylating agent that preferentially damages DNA in cancer cells that over-express certain biomarkers or harbor mutations in DNA repair pathways.
LP-184 is being developed for several targeted indications in cancer, including pancreatic cancer.
Lantern has begun discussions on the design of first-in-human clinical studies for LP-184.
Price Action: LTRN shares closed 2.9% lower at $13.06 on Wednesday.
Related content: Benzinga's Full FDA Calendar.

Posted In:

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.